| Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer L Magnani, A Stoeck, X Zhang, A Lánczky, AC Mirabella, TL Wang, ... Proceedings of the National Academy of Sciences 110 (16), E1490-E1499, 2013 | 188 | 2013 |
| Chromatin deregulation in disease AC Mirabella, B Foster, T Bartke Chromosoma 125 (1), 75-93, 2016 | 138 | 2016 |
| Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib AC Mirabella, AA Pletnev, SL Downey, BI Florea, TB Shabaneh, M Britton, ... Chemistry & biology 18 (5), 608-618, 2011 | 129 | 2011 |
| Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites PP Geurink, WA van der Linden, AC Mirabella, N Gallastegui, G de Bruin, ... Journal of medicinal chemistry 56 (3), 1262-1275, 2013 | 103 | 2013 |
| The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells M Kraus, J Bader, PP Geurink, ES Weyburne, AC Mirabella, T Silzle, ... Haematologica 100 (10), 1350, 2015 | 49 | 2015 |
| Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity OM Wilkins, SL Downey, ES Weyburne, DA Williams, AC Mirabella, ... Analytical biochemistry 451, 1-3, 2014 | 3 | 2014 |
